NCT02916602

A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605

A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 340 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A phase 3 study to evaluate efficacy and safety of HCP1401

Detailed description

A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of HCP1401 for stage 2 hypertension patients not controlled by HCP0605

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	HCP1401	amlodipine, Losartan, Chlorthalidone FDC
DRUG	HCP0605	amlodipine, Losartan FDC

Timeline

• Start date: 2015-04-01
• Primary completion: 2016-09-01
• Completion: 2016-09-01
• First posted: 2016-09-27
• Last updated: 2016-10-20

Locations

1 site across 1 country: South Korea